GPCR Quote, Financials, Valuation and Earnings

Metsera has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Metsera's return on equity of --.

Structure Therapeutics has a consensus price target of $75.81, signalling upside risk potential of 286.77%. On the other hand Metsera has an analysts' consensus of $55.00 which suggests that it could grow by 25.77%. Given that Structure Therapeutics has higher upside potential than Metsera, analysts believe Structure Therapeutics is more attractive than Metsera.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Metsera has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Metsera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Metsera pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Metsera quarterly revenues of --. Structure Therapeutics's net income of -$46.8M is higher than Metsera's net income of -$76.6M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Metsera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Metsera. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Structure Therapeutics's net margin of 21.63%. Structure Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

Structure Therapeutics has a consensus price target of $75.81, signalling upside risk potential of 286.77%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Structure Therapeutics has higher upside potential than Pfizer, analysts believe Structure Therapeutics is more attractive than Pfizer.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Structure Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Structure Therapeutics's net income of -$46.8M is lower than Pfizer's net income of $3B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Terns Pharmaceuticals's return on equity of --.

Structure Therapeutics has a consensus price target of $75.81, signalling upside risk potential of 286.77%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.14 which suggests that it could grow by 263.24%. Given that Structure Therapeutics has higher upside potential than Terns Pharmaceuticals, analysts believe Structure Therapeutics is more attractive than Terns Pharmaceuticals.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Terns Pharmaceuticals quarterly revenues of --. Structure Therapeutics's net income of -$46.8M is lower than Terns Pharmaceuticals's net income of -$23.9M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Viking Therapeutics's return on equity of --.

Structure Therapeutics has a consensus price target of $75.81, signalling upside risk potential of 286.77%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 185.37%. Given that Structure Therapeutics has higher upside potential than Viking Therapeutics, analysts believe Structure Therapeutics is more attractive than Viking Therapeutics.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Structure Therapeutics's net income of -$46.8M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.